RSV Vaccine for Older Adults
RSV vaccine is a single dose — not a yearly one. The CDC recommends it for all adults aged 75 and older, and for adults aged 50–74 at increased risk of severe RSV. A pregnancy version protects newborns and has its own guide.

Respiratory syncytial virus (RSV) is best known as a baby illness, but it also hospitalises large numbers of older adults each winter, causing pneumonia and worsening heart and lung disease. Three vaccines are licensed for older adults (Arexvy, Abrysvo and mRESVIA), all built around the virus's F protein.
The recommendation has been refined since the vaccines launched in 2023: it is now a clear recommendation for everyone 75 and older, and for people 50–74 whose risk of severe RSV is increased. One dose is currently recommended — this is not an annual vaccine, and people who have already had a dose do not need another at this time.
What this vaccine protects against
- Severe RSV lower respiratory tract disease — bronchiolitis and pneumonia in older adults.
- RSV-triggered worsening of chronic lung and heart disease, and hospitalisation.
Who should get it, and when
All adults aged 75 years and older: 1 dose of RSV vaccine.
Adults aged 50–74 years at increased risk of severe RSV: 1 dose. Increased risk includes chronic heart or lung disease, weakened immune systems, certain other chronic conditions, and living in a nursing home or long-term care facility. (This group was widened from 60–74 to 50–74 in the CDC's August 2025 update.)
Adults under 50, and adults 50–74 without risk factors, are not currently recommended RSV vaccination.
The best time to be vaccinated is late summer and early autumn, before RSV season — but the vaccine can be given at any time of year.
Pregnant people have a separate recommendation (Abrysvo at 32–36 weeks, in season) covered in the pregnancy guide; babies are protected by an antibody, not a vaccine — see the RSV antibody guide.
What happens at the vaccination visit
- A single injection into the upper arm.
- It can be given at the same visit as flu or COVID-19 vaccines.
How to prepare
- Check whether you have already had an RSV vaccine dose since 2023 — if so, no further dose is currently recommended.
- Tell the clinician about any previous severe allergic reaction to a vaccine.
What to expect afterwards
A sore arm, tiredness, headache and muscle aches for a day or two are the commonest effects.
Serious reactions are rare; small numbers of Guillain–Barré syndrome cases were reported after RSV vaccination in older adults in post-marketing monitoring, which regulators continue to track.
Who should not get it, or should ask first
- Anyone with a severe allergic reaction to a component of the specific RSV vaccine product should not receive that product.
- Moderate or severe illness is a reason to wait.
- Adults who have already received one RSV vaccine dose should not be revaccinated at this time, per current CDC guidance.
Benefits
- In trials the vaccines substantially reduced RSV lower respiratory tract disease in older adults, with protection lasting more than one season.
- One dose covers the highest-risk age group without a yearly schedule.
Limits and possible harms
- Mostly brief soreness and fatigue; rare neurological events (Guillain–Barré syndrome) have been reported after vaccination in older adults and are disclosed on the product information.
- Because only one dose is recommended, long-term duration of protection is still being studied.
Watch: related videos
Useful links and tools
More in Adult Vaccines
- Tetanus Boosters for Adults (Td & Tdap)
- Shingles Vaccine (Shingrix, RZV)
- Pneumococcal Vaccine for Adults (PCV)
- Mpox Vaccine (JYNNEOS)
Frequently asked questions
Is the RSV vaccine yearly, like flu?
No. CDC currently recommends a single dose for eligible adults — everyone 75 and older, and 50–74 year olds at increased risk. If you have already had an RSV vaccine, you do not need another dose at this time.
What is the difference between the RSV vaccine and the RSV antibody for babies?
The vaccine trains an older adult's (or a pregnant person's) own immune system. The baby product, nirsevimab, is not a vaccine at all — it is a ready-made antibody given directly to the baby for one season's protection. See the RSV antibody guide.
This guide explains how a vaccine is usually given and who it is generally offered to, following the CDC immunization schedules. It is general educational information only — not medical advice, and not a recommendation for you personally. Whether a vaccine is right for you depends on your age, health and history, so talk to your own clinician or pharmacist. If you are ill now, seek medical care promptly rather than waiting for a vaccination appointment.